MOUNJARO 15mg/0.5ml inj (Tirzepatide Vials) 15mg/0.5ml

Tirzepatide, the active ingredient in MOUNJARO, is a dual GIP and GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and reduces appetite, thereby improving glycemic control and promoting weight loss.

The dosage of MOUNJARO 15mg/0.5ml inj is determined by a healthcare provider based on individual patient needs. The initial dose is typically 2.5 mg once weekly, which may be gradually increased to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg once weekly, as tolerated.

The safety of MOUNJARO during pregnancy has not been established. It is not recommended for use during breastfeeding. Consult a healthcare provider before use if you are pregnant or breastfeeding.

To order MOUNJARO 15mg/0.5ml inj from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will reply with pricing, availability, shipping, and the import paperwork.

MOUNJARO is a dual GIP and GLP-1 receptor agonist, which distinguishes it from other diabetes medications that may target only one of these receptors. Its dual action provides enhanced glycemic control and weight loss benefits compared to some other diabetes medications.

MOUNJARO 15mg/0.5ml inj should be stored at 2-8°C, kept refrigerated, protected from light, and not frozen or shaken. It should be used within the expiration date and discarded properly if not used within the recommended time frame after opening.

MOUNJARO 15mg/0.5ml inj is administered via subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection should be rotated among different injection sites to avoid irritation.

The most serious risks to watch for with MOUNJARO include pancreatitis, hypoglycemia (when used with insulin or sulfonylureas), gallbladder problems, kidney problems, and allergic reactions. Patients should seek medical attention if they experience severe abdominal pain, signs of hypoglycemia, or symptoms of an allergic reaction.

MOUNJARO should not be used by individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or those with a history of severe gastrointestinal disease. It is also not recommended for use in patients with a history of pancreatitis or those with severe renal or hepatic impairment.